Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

Benzinga Newsdesk www.benzinga.com Positive 73.4%

Neg 0% Neu 0% Pos 73.4%

Comments

No comments yet. Be the first!